Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record.

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

Open access
Flaherty, Keith T., A. Rosen, Mark, F. Heitjan, Daniel, L. Gallagher, Maryann, Schwartz, Brian, D. Schnall, Mitchell, O'Dwyer, Peter J. · 2008 · Cancer Biology & Therapy

Abstract

BACKGROUND: The investigation of angiogenesis inhibitors is of particular interest in renal cell carcinoma (RCC), in which dysregulated blood vessel formation has been correlated with shortened survival. Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor. We conducted this study to (a) determine if sorafenib is anti-angiogenic, and (b) to relate anti-angiogenic effect to outcome. RESULTS: Four patients achieved partial response by WHO criteria (ORR 24%). Median time to progression (TTP) was 12.9 months. K(trans) decreased significantly during treatment with sorafenib (60.3% decline, 95% CI 46.1-74.6%). The percent decline in K(trans) and change in tumor size by CT scan were significantly associated with progression-free survival (p = 0.01 and 0.05, respectively). In addition, K(trans) at baseline was also significantly associated with progress-free survival (p = 0.02). PATIENTS AND METHODS: Seventeen patients with metastatic RCC underwent dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI). DCE-MRI was used to calculate the gadolinium exchange constant between blood and tumor interstitial tissue, K(trans). CONCLUSIONS: In patients with RCC, inhibition of tumor vascular permeability by sorafenib was associated with improved outcome. Moreover, baseline tumor vascular permeability, expected to be a poor prognosis factor, was a predictive marker of favorable response to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cbt.7.4.5624

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 193

Metadata

Authors
Flaherty, K. T., A. Rosen, M., F. Heitjan, D., L. Gallagher, M., Schwartz, B., D. Schnall, M., & O'Dwyer, P. J.
Venue
Cancer Biology & Therapy
Published
2008-04
Volume
7
Issue
4
Pages
496-501
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W1972528770
Cited by
193
References
0
FWCI
15.30
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. https://app.cochat.ai/papers/10.4161/cbt.7.4.5624
The paper
Flaherty, K. T., A. Rosen, M., F. Heitjan, D., L. Gallagher, M., Schwartz, B., D. Schnall, M., & O'Dwyer, P. J. (2008). Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biology & Therapy. https://doi.org/10.4161/cbt.7.4.5624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.